The key reasons why Cyclo Therapeutics Inc. (CYTH) is -51.86% away from 52-week high?
Cyclo Therapeutics Inc. (NASDAQ: CYTH) started the day on June 10, 2021, with a price increase of 11.71% at $10.11. During the day, the stock rose to $13.00 and sunk to $8.90 before settling in for the price of $9.05 at the close. Taking a more long-term approach, CYTH posted a 52-week range of $3.40-$21.00.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -1.00%. Meanwhile, its Annual Earning per share during the time was -4.30%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 19.70%. This publicly-traded company’s shares outstanding now amounts to $6.36 million, simultaneously with a float of $5.72 million. The organization now has a market capitalization sitting at $61.47 million. At the time of writing, stock’s 50-day Moving Average stood at $7.79.
Let’s gauge the efficiency of the firm, which has a total of 8 employees. It has generated 112,922 per worker during the last fiscal year. Meanwhile, its income per employee was -1,117,700. The stock had 6.14 Receivables turnover and 0.10 Total Asset turnover. For the Profitability, stocks gross margin was -192.33, operating margin was -991.99 and Pretax Margin of -989.80.
Cyclo Therapeutics Inc. (CYTH) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Drug Manufacturers – Specialty & Generic Industry. Cyclo Therapeutics Inc.’s current insider ownership accounts for 6.90%, in contrast to 1.70% institutional ownership. According to the most recent insider trade that took place on Apr 16, this organization’s Director bought 10,000 shares at the rate of 6.53, making the entire transaction reach 65,250 in total value, affecting insider ownership by 76,559. Preceding that transaction, on Mar 29, Company’s Chief Scientific Officer bought 1,000 for 7.46, making the whole transaction’s value amount to 7,460. This particular insider is now the holder of 18,350 in total.
Cyclo Therapeutics Inc. (CYTH) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 12/30/2020, the organization reported -$1.6 earnings per share (EPS) for the three months, lower than the consensus estimate (set at -$0.33) by -$1.27. This company achieved a net margin of -989.80 while generating a return on equity of -157.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Cyclo Therapeutics Inc.’s EPS increase for this current 12-month fiscal period is 19.70% and is forecasted to reach -1.93 in the upcoming year.
Cyclo Therapeutics Inc. (NASDAQ: CYTH) Trading Performance Indicators
Let’s observe the current performance indicators for Cyclo Therapeutics Inc. (CYTH). It’s Quick Ratio in the last reported quarter now stands at 3.80. The Stock has managed to achieve an average true range (ATR) of 0.95. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 68.30.
In the same vein, CYTH’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -6.02, and analysts are predicting that it will be -1.93 at the market close of one year from today.
Technical Analysis of Cyclo Therapeutics Inc. (CYTH)
If we take a close look at the recent performances of Cyclo Therapeutics Inc. (NASDAQ: CYTH), its last 5-days Average volume was 1.15 million that shows progress from its year to date volume of 0.8 million. During the previous 9 days, stock’s Stochastic %D was recorded 64.73% While, its Average True Range was 1.10.
Raw Stochastic average of Cyclo Therapeutics Inc. (CYTH) in the period of the previous 100 days is set at 38.24%, which indicates a major fall in contrast to 50.09% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 72.28% that was lower than 149.25% volatility it exhibited in the past 100-days period.